Anthony Gregg Lapointe

CIK 1331860 · last filed 2026-10-13

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$910.9K
Companies
11
Total Filings
62
Lifetime Open-Market Net
$0

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

RIGL price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
PO BOX 83216
GAITHERSBURG, MD 20883-3216
Formerly Known As
Lapointe Gregg Anthony (2005–2009)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SNGX Director — $0.35 — $0 6 2026-10-13
RIGL Director 18,250 $49.91 $910.9K $0 10 2026-05-19
Astria Therapeutics, Inc. (ATXS) Delisted Director — $12.58 — $0 6 2026-01-23
SOLIGENIX, INC. (SNGXW) Delisted Director — $0.01 — $0 5 2021-09-24
Astria Therapeutics, Inc. (CATB) Delisted Director — $8.54 — $0 5 2021-06-02
SCICLONE PHARMACEUTICALS INC (SCLN) Delisted Director — — — $0 10 2017-10-16
PLUS THERAPEUTICS, INC. (CYTX) Delisted Director — — — $0 1 2017-05-24
Raptor Pharmaceutical Corp (RPTP) Delisted Director 0 — — $0 4 2016-10-26
ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Director — — — $0 2 2016-06-21
QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted Director — — — $0 2 2010-01-04
QUESTCOR PHARMACEUTICALS INC (QSC) Delisted Director — — — $0 1 2007-01-04

Recent Filings · Page 2 of 7

62 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-12-15 SNGX Grant (A) — $0 EDGAR
2023-07-12 RIGL Grant (A) +25,000 $0 EDGAR
2023-06-06 Astria Therapeutics, Inc. (ATXS) Delisted Grant (A) — $0 EDGAR
2022-11-21 SNGX Grant (A) — $0 EDGAR
2022-06-21 Astria Therapeutics, Inc. (ATXS) Delisted Grant (A) — $0 EDGAR
2022-06-09 Astria Therapeutics, Inc. (ATXS) Delisted Grant (A) — $0 EDGAR
2022-05-23 RIGL Grant (A) +25,000 $0 EDGAR
2021-09-24 SOLIGENIX, INC. (SNGXW) Delisted Grant (A) — $0 EDGAR
2021-06-02 Astria Therapeutics, Inc. (CATB) Delisted Grant (A) — $0 EDGAR
2021-05-21 RIGL Grant (A) +25,000 $0 EDGAR
Showing 11–20 of 62
Page 2 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.